Close Menu

NEW YORK (GenomeWeb) – Germany-based LifeCodexx said today it has received CE marking for analysis software for a new noninvasive prenatal test for fetal trisomy 21 that is based on methylation-specific quantitative PCR.

The software, PrenaTest BioIT, is now cleared for the analysis of data from both LifeCodexx's existing next-generation sequencing-based PrenaTest and from its new methylation-specific qPCR-based qNIPT assay.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.